Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 60Prostatic Neoplasms 52Squamous Cell Carcinoma of Head and Neck 43Carcinoma, Non-Small-Cell Lung 39Head and Neck Neoplasms 37Lung Neoplasms 35Lymphoma 34Leukemia 22Brain Neoplasms 20Central Nervous System Neoplasms 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Glioblastoma 18Uterine Cervical Neoplasms 17Sarcoma 17Rectal Neoplasms 17Lymphoma, Follicular 16Esophageal Squamous Cell Carcinoma 16Esophageal Neoplasms 15Lymphoma, Large B-Cell, Diffuse 14Hodgkin Disease 14Burkitt Lymphoma 14Adenocarcinoma of Lung 13Oligodendroglioma 12Lymphoma, Non-Hodgkin 12Neoplasm Metastasis 11Astrocytoma 11Rhabdomyosarcoma 10Lymphoma, Large-Cell, Immunoblastic 10Neuroblastoma 9Nasopharyngeal Carcinoma 9

Interventions

padeliporfin 3palladium-bacteriopheophorbide 1enzalutamide 1darolutamide 1apalutamide 1Standard of Care 1Radiotherapy 1Prednisone 1Pluvicto 1Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Prostatic Diseases × Radiotherapy × Clear all
NCT06496581 2024-12-20

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

UNICANCER

Phase 3 Recruiting
500 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡